---
title: "Avita Medical’s Strategic Growth and Recovery: Analyst Recommends Buy Rating"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/264774378.md"
description: "Analyst Josh Jennings of TD Cowen has maintained a Buy rating on Avita Medical with a price target of $5.50. This recommendation is based on the company's strategic initiatives aimed at accelerating revenue growth, particularly through addressing reimbursement challenges for their RECELL product. The interim CEO is focused on expanding RECELL's use in medical settings and targeting key U.S. burn and trauma centers, positioning the company for growth despite current challenges. The synergistic portfolio is expected to enhance sales operations and adoption in acute wound care."
datetime: "2025-11-07T03:15:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264774378.md)
  - [en](https://longbridge.com/en/news/264774378.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264774378.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/264774378.md) | [繁體中文](https://longbridge.com/zh-HK/news/264774378.md)


# Avita Medical’s Strategic Growth and Recovery: Analyst Recommends Buy Rating

Analyst Josh Jennings of TD Cowen maintained a Buy rating on Avita Medical, retaining the price target of $5.50.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

Josh Jennings has given his Buy rating due to a combination of factors that highlight Avita Medical’s potential for growth and recovery. The company’s management has outlined strategic initiatives aimed at accelerating revenue growth, particularly through easing reimbursement challenges for their RECELL product. With finalized pricing decisions and progress in VAC approvals for Cohealyx and PermeaDerm, the company is poised to put its product portfolio back on track by 2026.  
Furthermore, the interim CEO is focusing on improving execution by expanding the use of RECELL across various medical settings and ensuring a successful transition of the commercial organization. By targeting approximately 200 key U.S. burn and trauma centers, Avita Medical is tapping into a significant market opportunity. Despite current challenges, the CEO is confident that normalizing reimbursement transitions and hospital reviews will position the company to strengthen execution and advance its mission in acute wound care. The synergistic portfolio, with its three growth drivers, is expected to benefit from enhanced sales operations and increased adoption.

### 相关股票

- [Avita Medical (RCEL.US)](https://longbridge.com/zh-CN/quote/RCEL.US.md)

## 相关资讯与研究

- [Here's How Much $100 Invested In Global X Artificial Intelligence & Technology ETF 15 Years Ago Would Be Worth Today](https://longbridge.com/zh-CN/news/280818282.md)
- [TCS Rewires Enterprise Tech With AI](https://longbridge.com/zh-CN/news/280993412.md)
- [Will This All-Weather ETF Live Up to Its Name?](https://longbridge.com/zh-CN/news/281059401.md)
- [electroCore study shows nVNS cuts symptoms in chronic mild TBI, PTSD patients](https://longbridge.com/zh-CN/news/281363514.md)
- [Is This the One ETF to Rule Them All?](https://longbridge.com/zh-CN/news/280916559.md)